



NHMRC Centre for Blood Transplant and Cell Therapy

Supported by Leukaemia Foundation

The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, investigators from the CBTCT will review major topics in stem cell transplantation and cell therapy, highlighting how the activities of the CBTCT are addressing current challenges in stem cell transplantation. The final seminar of the 2020 CBTCT webinar series features Professor David Curtis reviewing the significance and potential management approaches to minimal residual disease in the peri-allogeneic blood transplant setting, followed by Professor David Ritchie highlighting the importance of the cellular therapies laboratory with the emergence of commercially available chimeric antigen receptor (CAR) T cell therapies.

Speakers



Professor David Curtis

The Alfred Hospital and Monash
University

*Minimal residual disease before and
after allogeneic blood transplant*



Professor David Ritchie

Royal Melbourne Hospital and
University of Melbourne

*The role of the translational
laboratory in CAR T cell research*

WEBINAR

Centre for Blood Transplant and Cell Therapies Webinar Series

Monday 26 October 2020
12pm (AEDT)

ALL WELCOME TO ATTEND

No registration required

JOIN WEBINAR

<https://bloodcelltherapy.org.au/>

